Primarily, DLBCL has alterations in genes involved in B-cell differentiation pathways, such as chromosomal rearrangements of the BCL6 locus and mutations/deletions in PRDM1 [10,11,12] and IRF8 [13,14] and BCR/NF-κB signaling, such as CD79B/A, BCL10, TNFAIP3, and CARD11 [11,12,14,15,16,17,18,19,20]. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.